Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

NCT00884845 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumors

Interventions

DRUG: PM02734 and erlotinib
DRUG: Erlotinib

Sponsor

PharmaMar